ABL Bio Inc. (KOSDAQ:298380)

ABL Bio Statistics

Total Valuation

ABL Bio has a market cap or net worth of KRW 6.13 trillion. The enterprise value is 6.04 trillion.

Market Cap	6.13T
Enterprise Value	6.04T

Important Dates

The next estimated earnings date is Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

ABL Bio has 55.13 million shares outstanding. The number of shares has increased by 0.80% in one year.

Current Share Class	55.13M
Shares Outstanding	55.13M
Shares Change (YoY)	+0.80%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	26.32%
Owned by Institutions (%)	15.16%
Float	40.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	186.02
PS Ratio	64.57
PB Ratio	33.35
P/TBV Ratio	34.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-294.24
EV / Sales	63.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-136.46

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.24.

Current Ratio	2.35
Quick Ratio	2.32
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-0.98
Interest Coverage	-82.43

Financial Efficiency

Return on equity (ROE) is -17.32% and return on invested capital (ROIC) is -8.54%.

Return on Equity (ROE)	-17.32%
Return on Assets (ROA)	-7.58%
Return on Invested Capital (ROIC)	-8.54%
Return on Capital Employed (ROCE)	-11.97%
Revenue Per Employee	930.69M
Profits Per Employee	-201.20M
Employee Count	102
Asset Turnover	0.52
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +188.15% in the last 52 weeks. The beta is 0.71, so ABL Bio's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	+188.15%
50-Day Moving Average	94,504.00
200-Day Moving Average	66,033.50
Relative Strength Index (RSI)	65.45
Average Volume (20 Days)	632,306

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABL Bio had revenue of KRW 94.93 billion and -20.52 billion in losses. Loss per share was -425.01.

Revenue	94.93B
Gross Profit	94.88B
Operating Income	-22.12B
Pretax Income	-20.52B
Net Income	-20.52B
EBITDA	-19.40B
EBIT	-22.12B
Loss Per Share	-425.01

Balance Sheet

The company has 137.86 billion in cash and 43.38 billion in debt, giving a net cash position of 94.47 billion or 1,713.82 per share.

Cash & Cash Equivalents	137.86B
Total Debt	43.38B
Net Cash	94.47B
Net Cash Per Share	1,713.82
Equity (Book Value)	183.83B
Book Value Per Share	3,728.56
Working Capital	80.45B

Cash Flow

In the last 12 months, operating cash flow was -23.58 billion and capital expenditures -20.67 billion, giving a free cash flow of -44.25 billion.

Operating Cash Flow	-23.58B
Capital Expenditures	-20.67B
Free Cash Flow	-44.25B
FCF Per Share	-802.71

Margins

Gross margin is 99.94%, with operating and profit margins of -23.30% and -21.62%.

Gross Margin	99.94%
Operating Margin	-23.30%
Pretax Margin	-21.62%
Profit Margin	-21.62%
EBITDA Margin	-20.43%
EBIT Margin	-23.30%
FCF Margin	n/a

Dividends & Yields

ABL Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.80%
Shareholder Yield	-0.80%
Earnings Yield	-0.33%
FCF Yield	-0.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABL Bio has an Altman Z-Score of 17.96 and a Piotroski F-Score of 3.

Altman Z-Score	17.96
Piotroski F-Score	3